Table 1. Correlation between treatment with the combination of docetaxel and Aneustat and prostate cancer patient outcome (Oncomine).
| Clinical event | Clinical cohort | P value | q value | Risk of poor outcome |
|---|---|---|---|---|
|
Correlation with downregulated genes by treatment with the combinationa | ||||
| Survival | ||||
| >5 years | Setlur Prostate | 8.53E−21 | 5.13E−19 | 3.9 |
| >5 years | Nakagawa Prostate | 2.12E−10 | 7.72E−9 | 21.0 |
| >5 years | Nakagawa Prostate 2 | 1.18E−5 | 2.84E−4 | 10.3 |
| Recurrence | ||||
| >5 years | Taylor Prostate 3 | 5.28E−35 | 5.05E−33 | 11.1 |
| >5 years | Nakagawa Prostate | 3.33E−9 | 1.12E−7 | 9.9 |
| Metastasis | ||||
| Taylor Prostate 3 | 1.12E−104 | 8.23E−102 | 9.4 | |
| Varambally Prostate | 7.45E−47 | 9.95E−45 | 4.0 | |
| Grasso Prostate | 1.10E−44 | 1.37E−42 | 3.9 | |
| LaTulippe Prostate | 6.28E−39 | 6.65E−37 | 7.1 | |
| Vanaja Prostate | 1.28E−34 | 1.21E−32 | 3.4 | |
| Holzbeierlein Prostate | 2.14E−14 | 9.86E−13 | 3.4 | |
|
Correlation with upregulated genes by treatment with the combinationb | ||||
| Recurrence | ||||
| >5 years | Taylor Prostate 3 | 6.59E−7 | 6.82E−5 | 2.1 |
| Metastasis | ||||
| Tamura Prostate | 2.71E−10 | 8.43E−8 | 2.8 | |
| Taylor Prostate 3 | 3.83E−21 | 1.71E−17 | 3.5 | |
| Yu Prostate | 1.43E−5 | 8.73E−4 | 2.5 | |
| Grasso Prostate | 1.42E−11 | 6.19E−9 | 2.2 | |
| LaTulippe Prostate | 3.62E−8 | 5.94E−6 | 2.4 | |
a
The calculation was based on downregulated genes following treatment with the combination and top 10% over-expressed genes in a short survival time, short recurrence time and metastatic prostate cancer patient cohorts.
b
The calculation was based on genes upregulated by treatment with the combination and top 10% under-expressed genes in a short survival time, short recurrence time and metastatic prostate cancer patient cohorts.